Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/clinchem/hvaa157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Commentary on "Full-Endoscopic Resection of a Lumbar Intradural Tumor (Schwannoma): Video Case Report and Description of the Surgical Technique".
Neurospine
December 2024
Department of Neurosurgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.
Neurol Ther
January 2025
Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.
Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).
View Article and Find Full Text PDFArticle Synopsis
- ADHD is a treatable condition, but children from racial-ethnic minority backgrounds often face barriers to timely and consistent treatment.
- Understanding the effects of systemic racism on healthcare can help improve ADHD care for these families.
- The experiences of families of color, along with guidance from healthcare professionals, can inform better clinical practices and foster equitable treatment for ADHD.
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.
Eur Respir J
January 2025
Assistance Publique Hôpitaux Paris (AP-HP), Hôpital Bichat, Département de Médecine Interne, Paris, France
Electronic health records (EHRs) have revolutionized the scale, speed, and granularity at which health data can be collated and summarized for epidemiologic purposes. However, population-level analyses of patient-level data are only as reliable as the accuracy or completeness of patient reporting, clinician data entry, and how systems are programmed. This commentary on a case argues that responsibility for the validity of EHR data should be shared among key stakeholders, including patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!